| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2012038944 |
| Title |
Matrix Metalloproteinase Inhibitors. |
| Abstract |
The present invention relates to methyl sulfonamides and N-formamides derivatives of formula (I) and to processes for their syntheses. The invention also relates to pharmacological compositions containing these derivatives and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatie arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation which leads to restenosis and ischemic heart failure, stroke, renal disease, tumor metastasis, and other inflammatory disorders characterized by over expression and over activation of an matrix metalloproteinase using the compounds. |
| Applicant(s) |
Ranbaxy Laboratories Limited |
| Representative Drug(s) |
D00ZZJ |
Drug Info
|
IC50 > 35 nM |
[1] |
| Patent ID |
WO2012038942 |
| Title |
Matrix Metalloproteinase Inhibitors. |
| Abstract |
This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart faliure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over-activation of matrix metalloproteinase using the compounds. |
| Applicant(s) |
Ranbaxy Laboratories Limited |
| Representative Drug(s) |
D0L6HL |
Drug Info
|
IC50 > 130 nM; IC50 < 10000 nM |
[1] |
| Patent ID |
WO2012014114 |
| Title |
Matrix Metalloproteinase Inhibitors. |
| Abstract |
The present invention relates to certain hydroxy propionic acid derivatives and the processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over activation of a matrix metalloproteinase using the compounds. |
| Applicant(s) |
Ranbaxy Laboratories Limited |
| Representative Drug(s) |
D09ATD |
Drug Info
|
IC50 > 1000 nM; IC50 < 10000 nM |
[1] |
